Serina Therapeutics Inc./$SER
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
Ticker
$SER
Sector
Primary listing
AMEX
Employees
16
Headquarters
Website
SER Metrics
BasicAdvanced
$29m
-
-$2.01
0.10
-
Price and volume
Market cap
$29m
Beta
0.1
52-week high
$7.92
52-week low
$1.22
Average daily volume
126k
Financial strength
Current ratio
4.176
Quick ratio
3.868
Long term debt to equity
17.977
Total debt to equity
18.93
Interest coverage (TTM)
-60.81%
Profitability
EBITDA (TTM)
-24.37
Gross margin (TTM)
-10,210.00%
Net profit margin (TTM)
-16,359.23%
Operating margin (TTM)
-18,803.08%
Effective tax rate (TTM)
-0.12%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-89.79%
Return on equity (TTM)
-221.93%
Valuation
Price to revenue (TTM)
163.934
Price to book
2.33
Price to tangible book (TTM)
2.33
Price to free cash flow (TTM)
-1.165
Free cash flow yield (TTM)
-85.80%
Free cash flow per share (TTM)
-1.699
Growth
Revenue change (TTM)
154.90%
Earnings per share change (TTM)
1,848.91%
3-year revenue growth (CAGR)
-29.53%
3-year earnings per share growth (CAGR)
138.36%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs